Comparative Pharmacology
Head-to-head clinical analysis: DOXY LEMMON versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY LEMMON versus TETRACHEL.
DOXY-LEMMON vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg orally or intravenously once daily.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 18-22 hours (mean ~20 hours) in adults with normal renal function. Clinically, this supports twice-daily dosing; prolonged in severe renal impairment (up to 40-60 hours) or hepatic impairment.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (approx. 40% as unchanged drug via glomerular filtration), biliary/fecal (approx. 60% as active and inactive metabolites, with significant enterohepatic recycling). Dose adjustment not required in mild renal impairment, but caution in severe hepatic dysfunction.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic